Feature | HRS | May 18, 2018| Dave Fornell

Heart Rhythm 2018 Late-breaking Studies

Heart Rhythm Society (HRS) live electrophysiology (EP) procedure case at the 2018 annual meeting. #HRS2018

A live EP case presentation during the 2018 Heart Rhythm meeting.

Here is an aggregation of all the news and late-breaking studies presented at the 2018 Heart Rhythm Society (HRS) Scientific Sessions in May. 

 

Late-breaking Studies:

• Catheter Ablation vs. Antiarrhythmic Drug Therapy for Atrial Fibrillation: Results of the CABANA Multicenter International Randomized Clinical Trial

Prevention of Arrhythmia Device Infection Trial (PADIT) — Novel Antibiotics Can Help Lower EP Device Infection Rates

• A Prospective, Blinded Evaluation of a Novel Filter Designed to Reduce Inappropriate Shocks by the Subcutaneous Implantable Defibrillator

• Three-year Outcomes After Botulinum Toxin Injections into Epicardial Fat Pads for Atrial Fibrillation Prevention in Patients Undergoing Coronary Artery Bypass Grafting

• Myocarditis Is an Underrecognized Etiology of Symptomatic Premature Ventricular Contractions - Insights from The Myocarditis and Ventricular Arrhythmia (MAVERIC) Registry

• Lower Adherence Direct Oral Anticoagulants Use Is Associated with Increased Risk of Thromboembolic Events Than Warfarin - Understanding the Real-world Performance of Systemic Anticoagulation in Atrial Fibrillation

• Atrial Fibrillation Burden and Impact on Mortality and Hospitalization — The CASTLE-AF Trial

• Device-related Thrombus After Left Atrial Appendage Closure with Watchman: Incidence, Predictors and Outcomes

Randomized Controlled Trial of Cardiac Contractility Modulation in Heart Failure: The FIX-HF-5C Study

Targeted Left Ventricular Lead Implantation in Non-Left Bundle Branch Block Patients: Primary Results of The Enhance CRT Pilot Study

• Intramural Needle Ablation for Refractory Ventricular Arrhythmias: 6-month Safety and Outcomes

 First In-human Data on the Globe Combined Multi-Electrode Contact Mapping and Ablation System for Treatment of Atrial Fibrillation

A Randomized Pragmatic Trial of Strategies of Permanent Pacemaker Versus Implantable Cardiac Monitor in Older Patients with Syncope and Bifascicular Block

Feasibility of Extravascular Pacing, Sensing and Defibrillation from a Novel Substernal lead: The Acute Extravascular Defibrillation, Pacing and Electrogram (ASD2) Study

AV Synchronous Pacing with a Ventricular Leadless Pacemaker: Primary Results from the Marvel Study

First Clinical Report of Atrial Fibrillation Ablation With Pulsed Electric Fields to Creat Elctroporation: An Ultra-Rapid, Tissue-Selective Modality for Cardiac Ablation

 

Other Key Heart Rhythm 2018 News: 

Atrial Fibrillation Patients Diagnosed With Carotid Atery Disease Face Increased Risk of Dementia

Five Key Takeaways From Heart Rhythm 2018

Heart Rhythm Society Recommends How to Prepare for Cybersecurity Threats to Cardiac Implantable Devices

Link Found Between Post-Traumatic Stress, Increased Risk of AFib

Marijuana Use Does Not Increase Risk of Arrhythmias, Might Reduce AFib Risk

Exposure to Air Pollution on Cold Days Can Trigger Sudden Cardiac Death in Women

Consumer Smart Watches Accurately Measure Paroxysmal Supraventricular Tachycardia

Radiofrequency Transseptal Needle Associated With 40 Percent Decrease in Silent Cerebral Embolism

FDA Clears Abbott's High-density Advisor HD Grid EP Mapping Catheter

Biosense Webster Launches Carto Vizigo Bi-Directional Guidance Sheath

Online ECG Monitoring Detects Paroxysmal AFib More Effectively Than Holter, Patch Methods

View photos from HRS 2018

Follow other HRS news

 

Link to the Heart Rhythm Society 2017 Late-Breaking Electrophysiology Trials
 

 

Other Late-breaking Cardiology Trials in 2018:

ACC 2018 Late-Breaking Trials

TCT 2018 Late-breaking Cardiovascular Clinical Trials

EuroPCR 2018 Late-breaking Trials in Interventional Cardiology

Heart Rhythm 2018 Late-breaking Studies

SCAI 2018 Late-breaking Clinical Trials

 

 
#HRS2018, #HRS18

Related Content

Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Ablation Systems | May 10, 2019 | Dave Fornell, Editor
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve
Ablation Reduces Risk of Dementia in Patients With AFib and Carotid Artery Disease
News | Ablation Systems | May 08, 2019
Even though many medical practitioners may opt not to perform procedures on higher-risk patients, new research finds it...
CardioFocus Announces European CE Mark Approval Of HeartLight X3 System
News | Ablation Systems | April 16, 2019
CardioFocus Inc. announced the European CE Mark approval of the HeartLight X3 Endoscopic Ablation System.
First Patient Treated With QDot Micro Ablation Catheter
News | Ablation Systems | February 04, 2019
Biosense Webster has enrolled and treated the first patient in its U.S. Investigational Device Exemption (IDE) study...
FDA Approves TactiCath Contact Force Ablation Catheter, Sensor Enabled
Technology | Ablation Systems | January 21, 2019
Abbott announced U.S. Food and Drug Administration (FDA) approval of the TactiCath Contact Force Ablation Catheter,...
First Patient Treated in STELLAR Atrial Fibrillation IDE Study
News | Ablation Systems | November 30, 2018
Johnson & Johnson Medical Devices Companies announced that Biosense Webster Inc. has enrolled and treated the first...
Overlay Init